GlobeNewswire by notified

Conagen unveils commercial production of high-purity non-GMO salidroside

Share

Ideal for adaptogen supplement solutions and natural preservatives in food and beverages.

Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing inflammation, protecting against oxidative stress in cells, and providing relief from depression, fatigue, and stress. Salidroside has also been used to alleviate high altitude sickness.

Unlike other salidroside products currently on the market, Conagen’s salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant --- the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions which are available from their pipeline partner, Sweegen.

Conagen’s 99% high-purity salidroside, made by bioconversion, is ideal for non-GMO supplement solutions to formulate products with a sustainable and natural consumer appeal. It is readily soluble in water and is very formulable in food and beverage applications.

“We’re reimagining the way in which rare ingredients are sourced to make them safer and higher-quality for use in health-promoting products,” said Casey Lippmeier, Ph.D., senior vice president of innovation at Conagen. “Our bioconversion technology enables us to deliver non-GMO products. Through this technology, we’re unlocking salidroside’s great potential as a powerful active health ingredient and as a tool for food and beverage producers to adopt a more natural way to preserve food and beverages.”

Food and beverage producers benefit from Conagen’s salidroside as it also possesses antimicrobial properties, making it useful as a natural preservative solution for brands seeking alternatives to artificial preservatives. Salidroside expands Conagen’s portfolio of natural preservatives, such as Taxifolin BC-DHQ® and Rosavel™ rosmarinic acid, currently available from another pipeline partner, Blue California.

Stress reduction is popular among consumers, typically addressed by exercise or indulgence in food and beverages. More consumers are taking a holistic approach to their health, including their mental well-being and sleep. They are exploring adaptogens as one of the additional positive ways to add an edge to their diets and lifestyles.

“Salidroside is one of the rare, natural molecules with proven adaptogenic activities which correlates to stress reduction,” said Lippmeier. “Initially identified in botanical extracts, adaptogens are promising new options in the quest to relieve the stress of our daily lives. This trend opens new opportunities for supplement brands and food and beverage manufacturers to adopt a health-focused profile for their products.”

Conagen accelerated salidroside production by leveraging one of its proprietary molecular platforms, which have also been used to produce the clean antioxidants hydroxytyrosol and p-coumaric acid. Salidroside is a glucoside of tyrosol. Conagen’s antimicrobial and antioxidant compounds, hydroxytyrosol and p-coumaric acid are also now available through Blue California.

The inputs of fermentation are tightly controlled, dramatically reducing the chance of contamination with heavy metals, fungal toxins, and other unsafe materials that may be found in traditional medicine preparations. Rhodiola rosea extract is most commonly used in Europe and Asia. Its medicinal use for reducing stress and depression can be traced back to the Ming Dynasty in the classic medicinal scripture Compendium of Materia Medica.

###

About Conagen

We're making the impossible possible. Conagen is a product-focused synthetic biology R&D company with large-scale manufacturing capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and bioconversion technologies. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Coloplast A/S - Announcement no. 14/2022 - Articles of Association1.12.2022 17:33:41 CET | Press release

Articles of Association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 1 December 2022 are enclosed. Our mission Making life easier for people with intimate health care needs Our values Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us Our vision Setting the global standard for listening and responding For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: dkadim@coloplast.com Kristine Husted Munk Sr. Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: dkkhu@coloplast.com Press and media Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: dkpete@coloplast.com Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com This announ

Coloplast A/S - Selskabsmeddelelse nr. 14/2022 - Vedtægter1.12.2022 17:33:41 CET | pressemeddelelse

Vedlagt er vedtægter for Coloplast A/S som vedtaget på Coloplast A/S’ ordinære generalforsamling afholdt i dag den 1. december 2022. Vores mission At gøre livet lettere for mennesker med behov inden for intim sundhedspleje Vores værdier Nærhed... for bedre at forstå Passion... for at gøre en forskel Respekt og ansvarlighed... for at vejlede os Vores vision At sætte den globale standard for at lytte og handle For yderligere information, kontakt venligst Investorer og analytikere Anders Lonning-Skovgaard Koncerndirektør, CFO Tlf. 4911 1111 Aleksandra Dimovska Director, Investor Relations Tlf. 4911 1800 / 4911 2458 Email: dkadim@coloplast.com Kristine Husted Munk Sr. Manager, Investor Relations Tlf. 4911 1800 / 4911 3266 Email: dkkhu@coloplast.com Presse og medier Peter Mønster Sr. Media Relations Manager Tlf. 4911 2623 Email: dkpete@coloplast.com Adresse Coloplast A/S Holtedam 1 3050 Humlebæk Danmark CVR nr. 69749917 Hjemmeside www.coloplast.com Denne selskabsmeddelelse fås på dansk og e

Hexatronic completes previously announced acquisition of KNET1.12.2022 17:30:00 CET | Press release

Press release December 1, 2022 Gothenburg, Sweden Hexatronic completes previously announced acquisition of KNET Hexatronic Group AB (publ) ("Hexatronic") has today, December 1, 2022, completed the previously announced acquisition of KNET CO., LTD ("KNET") - one of the global leaders within microduct solutions for the telecommunication industry. With the acquisition of KNET, Hexatronic will get access to a high quality and high-volume production plant strategically located to serve Hexatronic’s businesses in North America, Europe and Oceania. The acquisition was announced on November 24, 2022 and took place via a transfer of shares and includes the land and buildings of the production plant. KNET will be consolidated into the Hexatronic Group from December 1, 2022. The acquisition has been fully financed with a senior bank loan. Gothenburg, December 1, 2022 Henrik Larsson Lyon CEO Hexatronic Group For more information, please contact: Henrik Larsson Lyon, CEO Hexatronic Group, +46 706 5

Hexatronic tillträder tidigare offentliggjort förvärv av KNET1.12.2022 17:30:00 CET | Pressemelding

Pressmeddelande 1 december, 2022 Göteborg Sverige Hexatronic tillträder tidigare offentliggjort förvärv av KNET Hexatronic Group AB (publ) (”Hexatronic”) har idag den 1 december slutfört tidigare offentliggjort förvärv av KNET CO., LTD ("KNET") - en av de globala ledarna inom mikroduktlösningar för telekomindustrin. Förvärvet ger Hexatronic tillgång till en högkvalitativ produktionsanläggning med kapacitet för stora volymer som är strategiskt placerad för att leverera till Hexatronics verksamheter i Nordamerika, Europa och Oceanien. Förvärvet, som offentliggjordes den 24 november, har skett i form av en aktieöverlåtelse och inkluderar även produktionsanläggningens mark och byggnader. KNET konsolideras i Hexatronic från och med den 1 december 2022. Förvärvet har fullt ut finansierats med ett seniort banklån. Göteborg 1 december, 2022 Henrik Larsson Lyon VD Hexatronic Group För eventuella frågorkontakta: Henrik Larsson Lyon, VD Hexatronic Group, +46 706 50 34 00 Pernilla Lindén, CFO Hexa

Ålandsbanken Abp: Återköp av egna aktier 01.12.20221.12.2022 17:30:00 CET | Pressemelding

Ålandsbanken Abp Förändringar i återköpta aktier 01.12.2022 kl. 18:30 EET Ålandsbanken Abp: Återköp av egna aktier 01.12.2022 Datum 01.12.2022 Handelsplats Börsaffär Nasdaq Helsinki Oy (XHEL) Köp Aktie klass ALBBV Antal 440 st. Medelpris/aktie 36,2500 EUR Högsta pris/aktie 36,3000 EUR Lägsta pris/aktie 36,1000 EUR Totalt pris 15 950,00 EUR Ålandsbanken Abp:s innehav av egna aktier 01.12.2022: ALBBV 267 737 st. På Ålandsbanken Abp:s vägnar Skandinaviska Enskilda Banken AB (Publ) Antti Salakka Janne Tiihonen För vidare information vänligen kontakta: Peter Wiklöf, Vd och koncernchef, Ålandsbanken Abp, tfn +358 40 512 7505 Bilaga ALBBV SBB 01122022